---
schema_version: "secwatch.filing_event.v1"
accession: "0000200406-24-000071"
form_type: "8-K"
ticker: "JNJ"
cik: "0000200406"
company_name: "JOHNSON & JOHNSON"
filed_at: "2024-07-17T23:59:59+00:00"
generated_at: "2026-05-31T20:18:11.224202+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# J&J Q2 revenue up 4.3% but GAAP EPS falls 5.9%; adjusted EPS rises 10.2%

## Summary
- Q2 2024 revenue $22.4B, +4.3% YoY; GAAP diluted EPS $1.93, -5.9% YoY; adjusted diluted EPS $2.82, +10.2% YoY.
- Innovative Medicine (ex-COVID) revenue $14.3B, +6.5% operational; MedTech revenue $7.96B, +2.2% reported.
- GAAP net earnings from continuing ops $4.69B, -12.8% YoY, impacted by $194M IPR&D impairments and prior-year gains.
- Adjusted net earnings from continuing ops $6.84B, +1.6% YoY; effective tax rate up to 18.5% from 14.7%.
- Share repurchase reduced diluted share count to 2,422M from 2,626M YoY, boosting adjusted EPS growth.

## SEC filing metadata
- accession: 0000200406-24-000071
- form_type: 8-K
- ticker: JNJ
- cik: 0000200406
- company_name: JOHNSON & JOHNSON
- filed_at: 2024-07-17T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/200406/000020040624000071/0000200406-24-000071-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/200406/000020040624000071/jnj-20240717.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000200406-24-000071
- JSON: https://secwatch.observer/filing/0000200406-24-000071.json
- Plain text: https://secwatch.observer/filing/0000200406-24-000071.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.